HSP90AA1 and neoplasm: Furthermore, we demonstrate that HSP90A inhibition with AUY-922 renders tumor susceptible to T cell-based immunotherapy including ACT and anti-PD-1 therapy, and leads to increase of the infiltration of tumor-reactive T cells via amplification of anti-tumor immunity.